With the EU approval of COPD med Duaklir, AstraZeneca is getting exactly what it wanted when it sealed a deal for Almirall's respiratory portfolio earlier this month. The only problem? Calling the market crowded is an understatement.
Want a surefire way to shake up a drug market? Introduce new medication options that make it easier for patients to manage their disease. MS drugmakers would know; their market is all of a sudden full of them.
For one, a game-changing trio of pills is providing an alternative to injections. Novartis' Gilenya hit first in September 2010, followed by Sanofi's Aubagio and Biogen Idec's Tecfidera. Two of those three, Gilenya and Tecfidera, nabbed spots on our list of Top 15 drug launch superstars after hitting the ground running. They're primed to keep moving up the food chain, too.
Drugmakers raise U.S. prices to make more money. This isn't a surprise to anyone. It's a basic business strategy, and the U.S. market is among the few where pharma companies still have considerable pricing power. But thanks to a steady flow of expensive new cancer therapies--and a public brouhaha over the cost of next-gen treatments for hepatitis C--drug prices are on center stage.
Prominent cancer doctors have balked at adopting a new Sanofi drug, Zaltrap, because they decided its benefits weren't worth the cost. Pharmacy benefits managers, notably Express Scripts, have nixed drugs from their formularies in favor of competing--and less expensive--options. And Gilead Sciences' pricing poster child Sovaldi has private payers and government programs so spooked, they're considering limiting its use to the sickest patients, at least until they can use soon-to-be-approved rivals to negotiate better pricing. Click here to read the full report on FiercePharmaMarketing >>
This is the best FiercePharma reading experience we've ever created. Swipe right-to-left within articles to quickly scan the latest news. Get breaking news alerts sent to your mobile device so you're the first to know when a major story unfolds. Download it today; the app is an essential complement to our e-mail newsletter and website.
Have something to say? Join the conversation at
FiercePharma's LinkedIn group.
Ipsen has its eye on swelling its North American presence from 5% to 30% of its overall business by 2020, with a new indication on the way for cancer drug Somatuline that it thinks could help it get there. If the launch is right, that is.
The star of personalized medicine is just the company you'd expect: Roche, with its drug-plus-diagnostic approach to cancer R&D and its stable of blockbuster HER2-positive therapies, and a total of almost $20 billion in sales from its targeted drugs.
For Sanofi's upcoming rollout of Afrezza, the inhaled insulin developed by MannKind, the crowd is already assembling.
Mobile apps and digital tracking and the quantified self. A world of opportunities for drugmakers, right? That's the hypothesis. Digital data-gathering and monitoring won't just help patients manage their conditions and take their meds on time, but also persuade skeptical payers that products are worth their cost.
The FDA has decided that the death last month of a patient taking Biogen Idec's hot multiple sclerosis pill Tecfidera was important enough to mention on Tecfidera labels.
Sanofi finally has its FDA approval for Lemtrada. The multiple sclerosis drug, previously rejected by the agency, will hit the market after a trio of new oral treatments. It will come with a boxed warning and faces tight controls on prescribing and distribution.